ECE2018 Poster Presentations: Reproductive Endocrinology Male Reproduction (17 abstracts)
Hematological indices in congenital hypogonadism and the effect of testosterone replacement therapy: A retrospective study
Cem Haymana 1 , Ibrahim Demirci 1 , Mustafa Dinc 1 , Orhan Demir 1 , Onur Akın 2 , Coskun Meric 1 , Aydogan Aydogdu 1 , Alper Sonmez 1 & Omer Azal 1
1Gulhane Training and Research Hospital, department of Endocrinology and Metabolism, Ankara, Turkey; 2Gulhane Training and Research Hospital, department of Pediatric Endocrinology and Metabolism, Ankara, Turkey.
Introduction: Patients with hypogonadism are at increased risk for cardiovascular diseases. Mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) are hematological indices that are surrogate markers of adverse cardiovascular outcomes. This study investigated the platelet count, MPV levels, PLR, and NLR in patients with congenital hypogonadotrophic hypogonadism (CHH) and also studied the effect of testosterone replacement therapy (TRT) on these parameters.
Methods: A total of 67 young male patients with CHH (mean age: 21.5±2.0 years) and 68 healthy control subjects (mean age: 21.9±1.3 years) were enrolled in the study. The demographic parameters, homeostatic model assessment-insulin resistance (HOMA-IR), platelet count, MPV, PLR, and NLR were measured in patients with CHH and healthy controls before and after TRT.
Results: The patients had higher WC (P=0.04), triglycerides (P=0.02), insulin (P<0.001), HOMA-IR (P<0.001), platelet count (P=0.001), MPV (P=0.004), and PLR (P=0.003) levels and lower FSH, LH, and total testosterone (P<0.001 for all) levels than the healthy controls. After 5.85±2.13 months of TRT, the patients had significantly elevated BMI, WC, total testosterone, and HOMA-IR (P<0.001, P=0.001, P<0.001, and P=0.03, respectively) and decreased HDL-C levels (P<0.001); however, the alterations in platelet count, MPV levels, PLR, and NLR were not significant. There was also a significant correlation between total testosterone level and platelet count (r=−0.23, P=0.009), MPV (r=−0.0.22, P=0.013), and PLR. (r=−0.0.22, P=0.014).
Conclusion: The present study showed that platelet activation may play a pivotal role in the pathogenesis of cardiometabolic risk of patients with hypogonadism. Moreover, the short time TRT in treatment naïve young patients with CHH did not have any effect on the platelet count and size.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more